Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III Trial

November 14, 2026 updated by: Xuekui Liu

A Phase III, Open-Label, Multicenter, Randomized Clinical Trial of Neoadjuvant Camrelizumab Combined With Nab-Paclitaxel and Cisplatin in Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma

This is a Phase III, randomized, open-label, multicenter clinical study for patients with locally advanced, resectable head and neck squamous cell carcinoma (HNSCC).

The current standard treatment for this disease includes surgery or radiation, but many patients still experience tumor recurrence or metastasis. This study aims to evaluate whether adding an immunotherapy drug (Camrelizumab) to standard chemotherapy (nab-paclitaxel and cisplatin) before surgery or radiation can improve patient outcomes.

Participants will be randomly assigned in a 1:1 ratio to one of two groups:

Experimental Group: Receives 3 cycles of Camrelizumab combined with nab-paclitaxel and cisplatin as neoadjuvant (pre-operative) therapy.

Control Group: Receives 3 cycles of nab-paclitaxel and cisplatin as neoadjuvant therapy.

After 3 cycles of treatment, doctors will evaluate the tumors. Depending on the tumor response, its location, and the patient's preference, participants will then receive either surgery (radical resection) or radiation therapy combined with cisplatin.

The main goal of this study is to compare the 2-year Event-Free Survival (EFS) between the two groups to see if the addition of Camrelizumab can prevent the disease from progressing or coming back. We will also monitor overall survival, organ preservation rates, and safety.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Background:

Head and neck squamous cell carcinoma (HNSCC) is a common malignancy worldwide. For locally advanced resectable HNSCC, the standard treatment paradigm often involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. However, the 5-year survival rate remains suboptimal, and the optimal neoadjuvant regimen is still debated. Immunotherapy, particularly PD-1 inhibitors, has shown promising efficacy in recurrent/metastatic HNSCC. Our previous Phase II trial demonstrated that neoadjuvant Camrelizumab combined with nab-paclitaxel and cisplatin was safe and highly effective (Objective Response Rate of 89.6%). This Phase III study is designed to further validate these findings.

Study Design:

This is a randomized, open-label, multicenter, Phase III clinical trial. A total of 212 eligible patients with clinical stage III-IV (T2N2-3M0, T3-4N0-3M0, AJCC 8th) resectable HNSCC will be enrolled and randomized 1:1 to the experimental or control group.

Interventions:

Experimental Arm: Neoadjuvant Camrelizumab (200 mg, IV, Day 1) + nab-paclitaxel (260 mg/m², IV, Day 1) + cisplatin (60 mg/m², IV, Day 1) for 3 cycles (21-day cycle).

Control Arm: Neoadjuvant nab-paclitaxel (260 mg/m², IV, Day 1) + cisplatin (60 mg/m², IV, Day 1) for 3 cycles.

After 3 cycles, tumor response will be evaluated per RECIST v1.1. Patients with oropharyngeal, laryngeal, or hypopharyngeal cancer who achieve CR/PR and wish to preserve organ function will receive radical radiotherapy plus cisplatin; those with residual disease will undergo salvage surgery. Other patients will undergo radical surgery with organ preservation. Adjuvant therapy will be administered based on NCCN/CSCO guidelines and multidisciplinary team discussion.

Outcomes:

The primary endpoint is 2-year Event-Free Survival (EFS). Secondary endpoints include 2-year Overall Survival (OS), 2-year Progression-Free Survival (PFS), organ preservation rate, Disease Control Rate (DCR), Objective Response Rate (ORR), safety, quality of life (EORTC QLQ-C30 and QLQ-H&N35), and exploratory biomarker analysis (PD-L1 CPS, TMB, etc.).

Study Type

Interventional

Enrollment (Estimated)

212

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 1. Histologically and/or cytologically confirmed, previously untreated head and neck squamous cell carcinoma (diagnostic treatment excluded).

    2. Clinical stage T2N2-3M0 or T3-4N0-3M0 (Stage III-IV, AJCC 8th edition). 3. Age between 18 and 70 years. 4. ECOG Performance Status (PS) of 0 or 1. 5. Assessed by a head and neck oncologist as resectable with no distant metastasis.

    6. At least one evaluable lesion according to RECIST v1.1. 7. Adequate organ function to tolerate surgery:

  • Hematology: WBC ≥ 4000/μL, ANC ≥ 2.000/μL, Hemoglobin ≥ 9 g/dL, Platelets ≥ 100,000/μL.

  • Liver function: Bilirubin ≤ 1.5× ULN, AST/ALT ≤ 3× ULN, ALP ≤ 3× ULN, Albumin ≥ 3 g/dL.

  • Renal function: Serum creatinine ≤ 1.5× ULN or Cockcroft-Gault creatinine clearance ≥ 60 mL/min.

    8. Signed informed consent and willingness to comply with study procedures.

Exclusion Criteria:

  • 1. History of severe hypersensitivity to other monoclonal antibodies or any component of PD-1 monoclonal antibodies.

    2. Known or suspected autoimmune diseases, including dementia and epilepsy. 3. Recurrent disease, distant metastasis, concurrent other malignancies, or assessed as unresectable.

    4. Coagulation abnormalities (PT > 16s, APTT > 53s, TT > 21s, Fib < 1.5g/L), bleeding tendency, or receiving thrombolytic/anticoagulant therapy.

    5. Severe heart or lung disease; cardiac or pulmonary function below grade 3 (including grade 3).

    6. Laboratory test values within 7 days prior to enrollment not meeting the relevant standards.

    7. Prior use of anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies (or any other antibody targeting T-cell co-stimulation or checkpoint pathways).

    8. Comorbidities requiring long-term immunosuppressive therapy or systemic/local use of immunosuppressive doses of corticosteroids prior to enrollment.

    9. HIV positive; HBsAg positive with detectable HBV DNA (≥ 1000 cps/ml); positive blood screening for chronic hepatitis C (HCV antibody positive).

    10. Use of anti-tumor traditional Chinese herbal medicine within 4 weeks prior to randomization.

    11. Pregnant or lactating women.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Camrelizumab plus Chemotherapy

Patients receive neoadjuvant Camrelizumab (200 mg, IV, Day 1) combined with nab-paclitaxel (260 mg/m², IV, Day 1) and cisplatin (60 mg/m², IV, Day 1) every 3 weeks for 3 cycles, followed by surgery or radiotherapy based on tumor response.

Humanized anti-PD-1 monoclonal antibody administered intravenously at 200 mg on Day 1 of each 21-day cycle for 3 cycles.

Other Names:
  • SHR-1210

Administered intravenously at 260 mg/m² on Day 1 of each 21-day cycle for 3 cycles.

Other Names:
  • Albumin-bound paclitaxel

Administered intravenously at 60 mg/m² on Day 1 of each 21-day cycle for 3 cycles.

Other Names:
  • CDDP
Active Comparator: Chemotherapy Alone

Patients receive neoadjuvant nab-paclitaxel (260 mg/m², IV, Day 1) and cisplatin (60 mg/m², IV, Day 1) every 3 weeks for 3 cycles, followed by surgery or radiotherapy based on tumor response.

Administered intravenously at 260 mg/m² on Day 1 of each 21-day cycle for 3 cycles.

Other Names:
  • Albumin-bound paclitaxel

Administered intravenously at 60 mg/m² on Day 1 of each 21-day cycle for 3 cycles.

Other Names:
  • CDDP

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
2-year Event-Free Survival (EFS) Rate
Time Frame: 2 years from randomization

Event-Free Survival (EFS) is defined as the time from randomization to the first occurrence of any of the following events: disease progression that precludes surgery, local or distant recurrence, treatment termination due to toxicity or complications, or death from any cause. The rate at 2 years will be calculated.

2 years from randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
2-year Overall Survival (OS) Rate
Time Frame: 2 years from randomization

The percentage of patients alive at 2 years from randomization. If the patient died within 2 years, it will be censored at the last known alive date.

2 years from randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2027

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

January 1, 2030

Study Registration Dates

First Submitted

November 14, 2026

First Submitted That Met QC Criteria

November 14, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 14, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • B2024-782

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.